US Insurer Aetna to Reimburse Gilead Hepatitis Drug

The largest US health insurer, Aetna, has negotiated a discount for Gilead Sciences' hepatitis C treatment regime and said it plans to offer this as a preferred choice for its nearly 11 million commercial customers.

Aetna and other US insurers have resisted the high price of hepatitis C treatments.

Days after the Federal Drug Administration (FDA) approved AbbVie's Viekira Pak on Dec. 19 last year, the country's largest pharmacy benefit manager, Express Scripts, said it had negotiated a cheaper price.

In most cases, Express said it would no longer reimburse Gilead's Sovaldi - which costs $84,000 for the 12-week course of therapy - for patients who have the genotype 1 form of the disease (70% of US patients). This, it said, was unaffordable.

Gilead's latest Hepatitis treatment, Harvoni, combines Sovaldi with another drug. The one-pill, once-a-day treatment, which lists at $94,500 for 12 weeks, is claimed to boast cure rates well above 90%.

CVS Health Corp, one of the largest US managers of drug benefits, said it would give preferred status to the Gilead hepatitis C treatments and cover the AbbVie drug only as an exception.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.